Caption Management’s NovoCure NVCR Stock Holding History

Caption Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,000	Closed	-$1.94M	–	1880
2024 Q4	$1.94M	Buy	+65,000	New	+$1.38M	0.02%	703
2024 Q2	–	Sell	-196,200	Closed	-$3.07M	–	1403
2024 Q1	$3.07M	Buy	+196,200	New	+$2.89M	0.05%	425
2023 Q2	–	Sell	-275,000	Closed	-$16.5M	–	1315
2023 Q1	$16.5M	Buy	275,000 +103,700	+61%	+$8.29M	0.32%	71
2022 Q4	$12.6M	Buy	171,300 +36,000	+27%	+$2.71M	0.2%	126
2022 Q3	$10.3M	Buy	135,300 +46,500	+52%	+$3.63M	0.14%	169
2022 Q2	$6.17M	Buy	88,800 +38,800	+78%	+$2.92M	0.09%	294
2022 Q1	$4.14M	Sell	50,000 -88,000	-64%	-$6.48M	0.05%	497
2021 Q4	$10.4M	Hold	138,000	–	–	0.12%	223
2021 Q3	$16M	Buy	138,000 +88,000	+176%	+$13.3M	0.18%	135
2021 Q2	$11.1M	Buy	+50,000	New	+$9.73M	0.14%	177
2021 Q1	–	Sell	-119,100	Closed	-$20.6M	–	1287
2020 Q4	$20.6M	Buy	+119,100	New	+$16.3M	0.47%	42

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Caption Management's NVCR Position: Q2 2024 in Review

Caption Management sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 2,493 shares — an estimated $39K sold.

Caption Management first reported a position in NVCR in Q3 2020 and held it in 6 quarters. The position peaked at $9.59M in Q4 2020. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

Caption Management reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
Caption Management sold 2,493 NovoCure shares in Q2 2024, an estimated $39K.
Caption Management first reported a position in NovoCure in Q3 2020 and held it in 6 quarters.
Caption Management's NovoCure position peaked at $9.59M in Q4 2020.
236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Caption Management's 13F filing for Q2 2024, filed 14 Aug 2024.